Plus Therapeutics (NASDAQ: PSTV) Interview at the NYSE

15 Visioni

Grazie! Condividilo con i tuoi amici!

Non hai gradito questo video. Grazie per il feedback!

Published Oct 11, 2025

Discover how Plus Therapeutics (NASDAQ: PSTV), an innovative clinical-stage biopharmaceutical company, is advancing targeted radiotherapeutics and its CNSide® Diagnostics platform to diagnose and treat central nervous system (CNS) cancers. Filmed at the New York Stock Exchange, this exclusive Fintech TV interview highlights the company’s development pipeline in the fast-growing field of oncology therapeutics and the company's recent agreement for their CNSide® CSF Assay with UnitedHealthcare, covering over 51 million people.

Key Topics Covered

- Plus Therapeutics’ mission to transform cancer care with targeted radiotherapy
- Updates on the REYOBIQ™ platform for CNS cancers
- Progress in the ReSPECT clinical trials and the recent CNSide Diagnostics agreement with UnitedHealthcare
- Insights into FDA regulatory pathways, partnerships, and strategic growth
- Investment perspective: why PSTV stock is on the radar of biotech investors

About Plus Therapeutics and CNSide Diagnostics

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products

CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases.

Learn More:

PlusTherapeutics.com
CNSide-Dx.com @CNSideDiagnostics